The Global Neuralgia Therapy Partnering Terms and Agreements since 2010
report provides understanding and access to partnering deals and
agreements entered into by the world's leading healthcare companies.

The report provides an analysis of partnering deals. The majority of
deals are discovery or development stage whereby the licensee obtains a
right or an option right to license the licensors technology. These
deals tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated
deals terms provides critical insight into the negotiation process in
terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are
triggered - contract documents provide this insight where press releases
do not.

This report provides the reader with the following key benefits:

In-depth understanding of deal trends since 2010

Access to headline, upfront, milestone and royalty data

Comprehensive access to multiple deals entered into by the world's
biopharma companies since 2010